Compare GSK Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs UNICHEM LAB - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA UNICHEM LAB GSK PHARMA/
UNICHEM LAB
 
P/E (TTM) x 55.8 60.6 92.0% View Chart
P/BV x 11.7 0.7 1,801.6% View Chart
Dividend Yield % 1.3 2.1 63.5%  

Financials

 GSK PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
UNICHEM LAB
Mar-19
GSK PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs3,595292 1,231.2%   
Low Rs1,253182 688.5%   
Sales per share (Unadj.) Rs184.7167.7 110.1%  
Earnings per share (Unadj.) Rs26.3-3.6 -724.2%  
Cash flow per share (Unadj.) Rs29.25.9 490.8%  
Dividends per share (Unadj.) Rs20.004.00 500.0%  
Dividend yield (eoy) %0.81.7 48.9%  
Book value per share (Unadj.) Rs126.3372.3 33.9%  
Shares outstanding (eoy) m169.4070.38 240.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x13.11.4 928.7%   
Avg P/E ratio x92.2-65.3 -141.2%  
P/CF ratio (eoy) x83.139.9 208.4%  
Price / Book Value ratio x19.20.6 3,014.1%  
Dividend payout %76.1-110.2 -69.0%   
Avg Mkt Cap Rs m410,62616,680 2,461.8%   
No. of employees `0005.02.6 190.6%   
Total wages/salary Rs m5,3722,393 224.5%   
Avg. sales/employee Rs Th6,306.74,535.2 139.1%   
Avg. wages/employee Rs Th1,083.1919.8 117.8%   
Avg. net profit/employee Rs Th898.0-98.2 -914.4%   
INCOME DATA
Net Sales Rs m31,28111,801 265.1%  
Other income Rs m1,023984 104.0%   
Total revenues Rs m32,30412,785 252.7%   
Gross profit Rs m6,009-835 -719.7%  
Depreciation Rs m486674 72.1%   
Interest Rs m675 8.0%   
Profit before tax Rs m6,540-600 -1,090.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,373-343 -690.9%   
Profit after tax Rs m4,454-256 -1,743.0%  
Gross profit margin %19.2-7.1 -271.5%  
Effective tax rate %36.357.3 63.4%   
Net profit margin %14.2-2.2 -657.5%  
BALANCE SHEET DATA
Current assets Rs m20,06120,384 98.4%   
Current liabilities Rs m14,5435,029 289.2%   
Net working cap to sales %17.6130.1 13.6%  
Current ratio x1.44.1 34.0%  
Inventory Days Days57105 54.2%  
Debtors Days Days14135 10.4%  
Net fixed assets Rs m14,3439,023 159.0%   
Share capital Rs m1,694141 1,203.1%   
"Free" reserves Rs m19,70426,058 75.6%   
Net worth Rs m21,39826,199 81.7%   
Long term debt Rs m20-   
Total assets Rs m39,11331,496 124.2%  
Interest coverage x1,091.0-7.0 -15,642.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.4 213.5%   
Return on assets %11.4-0.6 -1,991.6%  
Return on equity %20.8-1.0 -2,134.1%  
Return on capital %31.9-2.0 -1,597.0%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5348,188 6.5%   
Fx outflow Rs m7,091596 1,189.8%   
Net fx Rs m-6,5577,592 -86.4%   
CASH FLOW
From Operations Rs m3,994-3,278 -121.8%  
From Investments Rs m-1,433-2,860 50.1%  
From Financial Activity Rs m-3,584-24 14,808.3%  
Net Cashflow Rs m-1,023-4,690 21.8%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 15.1 67.5%  
FIIs % 23.8 3.0 793.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 31.7 48.6%  
Shareholders   102,036 20,176 505.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   SUN PHARMA  DR. REDDYS LAB  NOVARTIS  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Oct 22, 2019 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS